Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025

Core Insights - Incannex Healthcare Inc. (NASDAQ: IXHL) reported a reduction in R&D expenses to $2.74 million in Q3 2025 from $3.28 million in the same quarter of the previous year, indicating effective cost containment measures [1] - SG&A expenses decreased significantly to $2.27 million from $4.14 million year-over-year, driven by strategic cost-saving initiatives [1] - The net loss for the quarter was reduced to $3.97 million from $6.03 million year-over-year, supported by improved operational efficiencies [1] - Cash and cash equivalents increased to $6.7 million from $2.1 million at the end of Q2 2024, attributed to recent financing activities and R&D tax incentive payments [1] Financial Management - IXHL plans to issue approximately $24.7 million worth of shares to repurchase all outstanding Series A Warrants, representing 347.2 million shares that could be dilutive, showcasing management's proactive approach to capital management [7] - The company secured $12.5 million in private placement funding, priced at-the-market [7] - A probability adjusted DCF model estimates a share valuation range of $5.30 to $5.94, with a midpoint of $5.61 [7]